{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "PARK2",
                "Protein_Change": {
                    "ref": "K",
                    "alt": "N",
                    "position": "27"
                },
                "variant_string_id": "PARK2 K27N"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkin is the causative gene for autosomal recessive juvenile Parkinsonism (AR - JP). Mutations in parkin cause loss of function and altered protein levels, leading to toxic buildup of parkin substrates. The ubiquitin - proteasome system is important for intracellular proteolysis, and parkin ubiquitinates misfolded proteins for proteasome - dependent degradation. Mutant parkin from AR - JP patients shows loss of ubiquitin ligase activity.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states the disease mechanism as loss of function of parkin in AR - JP due to mutations, leading to abnormal proteasomal binding and toxic substrate buildup.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Molecular dynamics (MD) simulation was used to study the effect of the K27N mutation on the structure of the Uld domain of parkin. The Uld domain is known to bind the Rpn10 subunit of the 26S proteasome, and the study aimed to understand how the mutation affects the structure and potentially the binding ability.",
                    "judgment": "Yes",
                    "reasoning": "MD simulation can effectively model the structural changes in the protein due to the mutation, which is relevant to the disease mechanism of impaired proteasomal binding. Thus, it reflects the disease pathogenesis.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "The paper does not mention basic controls (normal/negative/wild - type and abnormal/positive/null) and replicate information for the MD simulation.",
                    "judgment": "No",
                    "reasoning": "Since the paper does not provide information on basic controls and replicates for the MD simulation, we proceed to Sub - step 3b.",
                    "next_step_or_outcome": "Proceed to Sub - step 3b"
                },
                {
                    "step_name": "Sub - step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "extracted_paper_info": "The paper does not mention if the MD simulation is a broadly accepted, previously validated, or a commercial kit - based assay.",
                    "judgment": "No",
                    "reasoning": "As the paper lacks information indicating that the MD simulation is a broadly accepted, previously validated, or commercial kit - based assay, we do not use PS3/BS3.",
                    "next_step_or_outcome": "Do not use PS3/BS3"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "N/A"
            },
            "overall_conclusion": "The assessment for the PARK2 K27N variant did not meet the criteria for using PS3/BS3 as the MD simulation assay did not have information on basic controls, replicates, and was not shown to be an accepted/validated assay."
        },
        {
            "variant_id": {
                "Gene": "PARK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "Q",
                    "position": "33"
                },
                "variant_string_id": "PARK2 R33Q"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkin mutations cause autosomal recessive juvenile Parkinsonism (AR - JP) by leading to loss of function, altered protein levels, and toxic buildup of substrates due to impaired proteasomal binding in the ubiquitin - proteasome system.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly defines the disease mechanism related to parkin mutations in AR - JP.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Molecular dynamics (MD) simulation was used to study the effect of the R33Q mutation on the structure of the Uld domain of parkin. The Uld domain's interaction with the Rpn10 subunit of the 26S proteasome is relevant to the disease mechanism, and the MD simulation aims to understand the structural impact of the mutation on this interaction.",
                    "judgment": "Yes",
                    "reasoning": "MD simulation can effectively model the structural changes caused by the mutation, which is relevant to the disease - related impaired proteasomal binding. So, it reflects the disease pathogenesis.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "There is no mention of basic controls (normal/negative/wild - type and abnormal/positive/null) and replicate information for the MD simulation in the paper.",
                    "judgment": "No",
                    "reasoning": "Since the paper lacks information on basic controls and replicates for the MD simulation, we proceed to Sub - step 3b.",
                    "next_step_or_outcome": "Proceed to Sub - step 3b"
                },
                {
                    "step_name": "Sub - step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "extracted_paper_info": "The paper does not state that the MD simulation is a broadly accepted, previously validated, or a commercial kit - based assay.",
                    "judgment": "No",
                    "reasoning": "As the paper does not provide evidence that the MD simulation is a broadly accepted, previously validated, or commercial kit - based assay, we do not use PS3/BS3.",
                    "next_step_or_outcome": "Do not use PS3/BS3"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "N/A"
            },
            "overall_conclusion": "For the PARK2 R33Q variant, the MD simulation assay did not meet the requirements for using PS3/BS3 as there was no information on basic controls, replicates, and it was not shown to be an accepted/validated assay."
        },
        {
            "variant_id": {
                "Gene": "PARK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "P",
                    "position": "42"
                },
                "variant_string_id": "PARK2 R42P"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkin mutations cause AR - JP through loss of function, leading to abnormal proteasomal binding and toxic substrate accumulation in the ubiquitin - proteasome system.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly outlines the disease mechanism associated with parkin mutations in AR - JP.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Molecular dynamics (MD) simulation was used to study the R42P mutation's effect on the Uld domain of parkin. The Uld domain's role in binding to the Rpn10 subunit of the 26S proteasome is relevant to the disease mechanism, and the MD simulation helps understand the structural changes due to the mutation.",
                    "judgment": "Yes",
                    "reasoning": "MD simulation can model the structural changes caused by the mutation, which is related to the disease - associated impaired proteasomal binding. Thus, it reflects the disease pathogenesis.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "The paper does not mention basic controls (normal/negative/wild - type and abnormal/positive/null) and replicate information for the MD simulation.",
                    "judgment": "No",
                    "reasoning": "Lack of information on basic controls and replicates in the paper for the MD simulation leads us to proceed to Sub - step 3b.",
                    "next_step_or_outcome": "Proceed to Sub - step 3b"
                },
                {
                    "step_name": "Sub - step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "extracted_paper_info": "The paper does not indicate that the MD simulation is a broadly accepted, previously validated, or a commercial kit - based assay.",
                    "judgment": "No",
                    "reasoning": "Without evidence that the MD simulation is a broadly accepted, previously validated, or commercial kit - based assay, we do not use PS3/BS3.",
                    "next_step_or_outcome": "Do not use PS3/BS3"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "N/A"
            },
            "overall_conclusion": "For the PARK2 R42P variant, the MD simulation assay did not meet the criteria for using PS3/BS3 as there was no information on basic controls, replicates, and it was not shown to be an accepted/validated assay."
        },
        {
            "variant_id": {
                "Gene": "PARK2",
                "Protein_Change": {
                    "ref": "K",
                    "alt": "A",
                    "position": "48"
                },
                "variant_string_id": "PARK2 K48A"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkin mutations lead to AR - JP by causing loss of function, altered protein levels, and abnormal proteasomal binding in the ubiquitin - proteasome system, resulting in toxic substrate buildup.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly defines the disease mechanism related to parkin mutations in AR - JP.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Molecular dynamics (MD) simulation was used to study the K48A mutation's impact on the Uld domain of parkin. The Uld domain's interaction with the Rpn10 subunit of the 26S proteasome is relevant to the disease mechanism, and the MD simulation aims to understand the structural changes due to the mutation.",
                    "judgment": "Yes",
                    "reasoning": "MD simulation can effectively model the structural changes caused by the mutation, which is relevant to the disease - related impaired proteasomal binding. So, it reflects the disease pathogenesis.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "There is no mention of basic controls (normal/negative/wild - type and abnormal/positive/null) and replicate information for the MD simulation in the paper.",
                    "judgment": "No",
                    "reasoning": "Since the paper lacks information on basic controls and replicates for the MD simulation, we proceed to Sub - step 3b.",
                    "next_step_or_outcome": "Proceed to Sub - step 3b"
                },
                {
                    "step_name": "Sub - step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "extracted_paper_info": "The paper does not state that the MD simulation is a broadly accepted, previously validated, or a commercial kit - based assay.",
                    "judgment": "No",
                    "reasoning": "As the paper does not provide evidence that the MD simulation is a broadly accepted, previously validated, or commercial kit - based assay, we do not use PS3/BS3.",
                    "next_step_or_outcome": "Do not use PS3/BS3"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "N/A"
            },
            "overall_conclusion": "For the PARK2 K48A variant, the MD simulation assay did not meet the requirements for using PS3/BS3 as there was no information on basic controls, replicates, and it was not shown to be an accepted/validated assay."
        },
        {
            "variant_id": {
                "Gene": "PARK2",
                "Protein_Change": {
                    "ref": "V",
                    "alt": "E",
                    "position": "56"
                },
                "variant_string_id": "PARK2 V56E"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkin mutations cause AR - JP through loss of function, abnormal proteasomal binding, and toxic substrate accumulation in the ubiquitin - proteasome system.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly defines the disease mechanism associated with parkin mutations in AR - JP.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Molecular dynamics (MD) simulation was used to study the V56E mutation's effect on the Uld domain of parkin. The Uld domain's role in binding to the Rpn10 subunit of the 26S proteasome is relevant to the disease mechanism, and the MD simulation helps understand the structural changes due to the mutation.",
                    "judgment": "Yes",
                    "reasoning": "MD simulation can model the structural changes caused by the mutation, which is related to the disease - associated impaired proteasomal binding. Thus, it reflects the disease pathogenesis.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "The paper does not mention basic controls (normal/negative/wild - type and abnormal/positive/null) and replicate information for the MD simulation.",
                    "judgment": "No",
                    "reasoning": "Lack of information on basic controls and replicates in the paper for the MD simulation leads us to proceed to Sub - step 3b.",
                    "next_step_or_outcome": "Proceed to Sub - step 3b"
                },
                {
                    "step_name": "Sub - step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "extracted_paper_info": "The paper does not indicate that the MD simulation is a broadly accepted, previously validated, or a commercial kit - based assay.",
                    "judgment": "No",
                    "reasoning": "Without evidence that the MD simulation is a broadly accepted, previously validated, or commercial kit - based assay, we do not use PS3/BS3.",
                    "next_step_or_outcome": "Do not use PS3/BS3"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "N/A"
            },
            "overall_conclusion": "For the PARK2 V56E variant, the MD simulation assay did not meet the criteria for using PS3/BS3 as there was no information on basic controls, replicates, and it was not shown to be an accepted/validated assay."
        }
    ]
}